Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association CongressAccesswire • 06/01/26
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026Accesswire • 05/28/26
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateAccesswire • 05/05/26
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual MeetingAccesswire • 03/28/26
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's WhyZacks Investment Research • 03/20/26
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/20/26
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment TranscriptSeeking Alpha • 03/18/26
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque PsoriasisAccesswire • 03/18/26
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraBusiness Wire • 03/02/26
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateAccesswire • 02/25/26
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateAccesswire • 02/25/26
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026Accesswire • 02/24/26
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock PerformanceThe Motley Fool • 02/16/26
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover TaxesThe Motley Fool • 02/01/26
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026Accesswire • 01/07/26
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)Business Wire • 01/05/26
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia VeraBusiness Wire • 12/06/25
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/06/25